Saltar a búsqueda.
 Dow Descenso0.11% Nasdaq Ascenso0.09%

Peregrine Pharmaceuticals, Inc. (PPHM)

-NasdaqCM
0.30 Ascenso 0.00(1.26%) 2 de dic 4:00 PM GMT-5
PerfilVer Perfil de:
Peregrine Pharmaceuticals, Inc.
14282 Franklin Avenue
Tustin, CA 92780
United States - Mapa
Teléfono: 714-508-6000
Sitio web: http://www.peregrineinc.com

Detalles 
Indices:N/C
Sector:Healthcare
Industria:Biotechnology
Empleados a tiempo completo:281

Resumen empresarial (en inglés) 

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment of cancer in the United States. It’s lead immunotherapy candidate bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company also provides integrated current good manufacturing practices services from cell line development to commercial bio manufacturing for its third-party customers. In addition, its services comprise cGMP clinical and commercial manufacturing utilizing stainless steel and single use bioreactor technology, purification, bulk packaging, stability testing, regulatory strategy and related support. The company has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; Merck KGaA; and National Comprehensive Cancer Network, as well as collaboration agreement with AstraZeneca PLC and Memorial Sloan Kettering Cancer Center. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

Estadísticas clave


Sitios web de la empresa 
Home Page
Búsqueda en Yahoo! de:
Más sobre Peregrine Pharmaceuticals, Inc.

Ejecutivos 
 PagarEjercido
Mr. Steven W. King , 52
Chief Exec. Officer, Pres, Director, Chief Exec. Officer of Avid Bioservices Inc and Pres of Avid Bioservices Inc
933.00mil0.00
Mr. Paul J. Lytle CPA, 48
Chief Financial Officer
596.00mil0.00
Mr. Mark R. Ziebell J.D., 52
VP, Gen. Counsel and Corp. Sec.
481.00mil0.00
Mr. Joseph S. Shan M.P.H., 43
Head of Clinical & Regulatory Affairs and VP of Clinical & Regulatory Affairs
473.00mil0.00
Dr. Shelley P. M. Fussey Ph.D., 50
VP of Intellectual Property
407.00mil0.00
Las cantidades son con fecha de dic 31, 2016 y los valores de compensación son los del último año fiscal que finalizó en dicha fecha. Por sueldo se entiende salario, bonificaciones, etc. Ejercido representa el valor de las opciones ejercido durante el año fiscal.
Divisa en USD.
Ver ejecutivos